Chongqing Genrix Biopharmaceutical Co., Ltd. Stock: price and insider trades · China
智翔金泰
No insider purchase over the last 90 days. The latest, by 蒋仁生, was filed 08 Jan 2024.
Chongqing Genrix Biopharmaceutical Co., Ltd.: what insiders have been doing
Chongqing Genrix Biopharmaceutical Co., Ltd. belongs to the Health Care sector. Filings by its managers are published through SSE / SZSE (CSRC). No insider at Chongqing Genrix Biopharmaceutical Co., Ltd. has published a filing in the past twelve months. The most recent one dates from 8 January 2024.
Since 2023, the database holds 2 purchases and no sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Since the insiders bought
- -33.6%Entry CN¥36.80 · Close at T+365 CN¥24.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
About Chongqing Genrix Biopharmaceutical Co., Ltd.
智翔金泰 is a company operating in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on the development and commercialization of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
